VJHemOnc is committed to improving our service to you

ESH AL 2020 | MBG453 with hypomethylating agents in AML and high-risk MDS

VJHemOnc is committed to improving our service to you

Andrew Wei

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, details de results of the Phase 1b multicenter, open-label study of the anti-TIM-3 antibody MBG453 in combination with hypomethylating agents in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter